Newsfeeds - Spark Newswire

1 minute read

Lundbeck Out Licenses Flopped Alzheimer’s Drug In Wake Of Biogen’s Controversial Success With Aducanumab

Today, 8:24 PM

Privately-held Denovo Biopharma LLC has in-licensed global rights for idalopirdine from H. Lundbeck A/S (OTC:HLUYY) for all indications. The deal gives Lundbeck the option…

BIIB

1 minute read

10 Biggest Price Target Changes For Friday

By Lisa Levin

Today, 8:24 PM

Credit Suisse raised the price target for Capital One Financial Corporation (NYSE: COF) from $122 to $135. Capital One Financial shares rose 1.6% to close at $157.15 on Thursday.

AMWL

1 minute read

Thinking About Buying Stock Or Options In Walgreens, Enphase Energy Or Eli Lilly?

By Henry Khederian

Today, 8:24 PM

One of the most common questions traders have about stocks is “Why Is It Moving?” That’s why Benzinga created the Why Is It Moving, or WIIM, feature in Benzinga Pro. WIIMs are a one-sentence description as to why a stock is moving.

ENPH

2 minute read

Eli Lilly’s Debt Overview

By Benzinga Insights

Today, 8:24 PM

Over the past three months, shares of Eli Lilly (NYSE:LLY) increased by 26.91%. Before having a look at the importance of debt, let us look at how much debt Eli Lilly has.

LLY

1 minute read

Truist Securities Maintains Buy on Eli Lilly, Raises Price Target to $262

By Benzinga Newsdesk

Today, 8:24 PM

Truist Securities analyst Gregg Gilbert maintains Eli Lilly (NYSE:LLY) with a Buy and raises the price target from $225 to $262.

LLY

5 minute read

Attention Biotech Investors: Mark Your Calendar For July PDUFA Dates

By Shanthi Rexaline

Today, 8:24 PM

June was a month of plenty and also turned out to be a fruitful one from the perspective of Food and Drug Administration approvals. Regulatory reviews mostly produced positive verdicts, and rejections or no-decisions were few and far between.

ALBO

1 minute read

EC Selects Antibody Therapies, Arthritis Drug As Preferred COVID-19 Meds: Reuters

By Vandana Singh

Today, 8:24 PM

The European Commission (EC) picked four antibody treatments and a repurposed Eli Lilly And Co’s (NYSE:LLY) rheumatoid arthritis drug for an initial…

GSK

1 minute read

Eli Lilly To Look For Ways To Cut Insulin Costs After Walmart Debut: CNBC

By Vandana Singh

Today, 8:24 PM

Eli Lilly And Co (NYSE: LLY) CEO David Ricks said he welcomes new competition from Walmart Inc (NYSE: WMT) even as the retailer undercuts the company's insulin prices.

LLY

4 minute read

FDA
News

Eli Lilly Late Saturday Highlighted SURPASS-1 Results Were Published In ‘The Lancet,’ Showed Tirzepatide’s Superior A1C Blood Type, body Weight Reductions vs Placebo

By Benzinga Newsdesk

Today, 8:24 PM

Data presented at ADA's 81st Scientific Sessions® show the highest dose of tirzepatide (15 mg) reduced A1C by 2.07 percent and weight by 9.5 kg (20.9 lb., 11.0 percent) Majority of study population was

LLY

4 minute read

The Week Ahead In Biotech: Mediwound, Provention FDA Decisions, IPOs, Pending Clinical Readouts In Focus

By Shanthi Rexaline

Today, 8:24 PM

Biotech stocks reversed course and closed the week ended June 25 higher, thanks to the positive broader market sentiment.

AFMD